Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals (SYRS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Syros Pharmaceuticals 35 Cambridge Park Drive 4th Floor CAMBRIDGE MA 02140 USA

www.syros.com Employees: 68 P: 617-744-1340

Description:

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients with relapsed or refractory acute myeloid leukemia and relapsed high-risk myelodysplastic syndrome and SY-1365, a selective CDK7 inhibitor for acute leukemia which is in preclinical stage. Syros Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

Key Statistics

Overview:

Market Capitalization, $K 60,725
Enterprise Value, $K -37,575
Shares Outstanding, K 26,810
Annual Sales, $ 9,940 K
Annual Net Income, $ -164,570 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -3,710 K
EBIT, $ -126,700 K
EBITDA, $ -123,870 K
60-Month Beta 1.59
% of Insider Shareholders 12.26%
% of Institutional Shareholders 91.47%
Float, K 23,523
% Float 87.74%
Short Volume Ratio 0.61

Growth:

1-Year Return -2.02%
3-Year Return -95.03%
5-Year Return -95.65%
5-Year Revenue Growth 384.88%
5-Year Earnings Growth 75.39%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.70 on 07/31/24
Next Earnings Date 10/31/24
Earnings Per Share ttm -4.63
EPS Growth vs. Prev Qtr 2.86%
EPS Growth vs. Prev Year 49.63%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 09/19/22

SYRS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -1,419.05%
Return-on-Assets % -87.88%
Profit Margin % -1,655.63%
Debt/Equity 2.75
Price/Sales 6.80
Price/Cash Flow N/A
Price/Book N/A
Book Value/Share 0.56
Interest Coverage -31.08
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar